Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.98 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.98 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.98 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.98 |
| ▸ | SIRT1 | Q96EB6 | 15/20 | 0.98 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.98 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.98 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16372055 | 1.00 | SIRT1 (0.98) | SIRT1CHRM2ADRA2ACHRM1SLC6A2 | |
| SCHEMBL963877 | 0.99 | SIRT1 (1.00) | SIRT1CHRM2ADRA2ACHRM1SLC6A2 | |
| SCHEMBL29488567 | 0.99 | SIRT1 (1.00) | SIRT1CHRM2ADRA2ACHRM1SLC6A2 | |
| SCHEMBL2740335 | 0.92 | SIRT1 (0.86) | SIRT1CHRM2ADRA2ACHRM1SLC6A2 | |
| SCHEMBL2740379 | 0.91 | SIRT1 (0.85) | SIRT1CHRM2ADRA2ACHRM1SLC6A2 | |
| SCHEMBL2624518 | 0.91 | SIRT1 (0.85) | SIRT1CHRM2ADRA2ACHRM1SLC6A2 | |
| SCHEMBL2740334 | 0.91 | SIRT1 (0.85) | SIRT1CHRM2ADRA2ACHRM1SLC6A2 | |
| SCHEMBL2740430 | 0.90 | SIRT1 (0.83) | SIRT1CHRM2ADRA2ACHRM1SLC6A2 | |
| SCHEMBL2624519 | 0.89 | SIRT1 (0.82) | SIRT1CHRM2ADRA2ACHRM1SLC6A2 | |
| SCHEMBL2740333 | 0.89 | SIRT1 (0.82) | SIRT1CHRM2ADRA2ACHRM1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4608970-A2 | PD-1+CD38HICD8+ T CELLS AND USES THEREOF | Georgetown University (US) | 2025-09-03 | — | — | EP | disclosed |
| US-20250011881-A1 | MYC-HSF1 DUAL AMPLIFICATION AS A BIOMARKER FOR CANCER TREATMENT | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2025-01-09 | — | — | US | disclosed |
| CN-119242758-A | Application of SIRT1 gene in regulation of avian innate immune response | 中国农业科学院北京畜牧兽医研究所 | 2025-01-03 | — | — | CN | disclosed |
| US-12180509-B2 | Methods for reprograming non-pluripotent cells into pluripotent stem cells | BEIHAO STEM CELL AND REGENERATIVE MEDICINE RESEARCH INSTITUTE CO., LTD. (CN) | 2024-12-31 | — | — | US | disclosed |
| US-20240309458-A1 | MYC-HSF1 DUAL AMPLIFICATION AS A BIOMARKER FOR CANCER TREATMENT | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-09-19 | — | — | US | disclosed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | disclosed |
| WO-2024092108-A2 | PD-1+CD38HICD8+ T CELLS AND USES THEREOF | GEORGETOWN UNIVERSITY (US) | 2024-05-02 | — | — | WO | disclosed |
| EP-3384007-B1 | IMPROVED METHODS FOR REPROGRAMING NON-PLURIPOTENT CELLS INTO PLURIPOTENT STEM CELLS | BEIHAO STEM CELL AND REGENERATIVE MEDICINE RES INSTITUTE CO LTD (CN) | 2024-03-27 | — | — | EP | disclosed |
| CN-116003624-B | SIRT1 fusion proteins and uses thereof | 南京紫珑生物科技有限公司 | 2024-02-13 | — | — | CN | disclosed |
| US-20230265432-A1 | METHODS AND COMPOSITIONS FOR TREATING ACUTE MYELOID LEUKEMIA | Sanford Burnham Prebys Medical Discovery Institute | 2023-08-24 | — | — | US | disclosed |
| CN-116003624-A | SIRT1 fusion proteins and uses thereof | 南京紫珑生物科技有限公司 | 2023-04-25 | — | — | CN | disclosed |
| CN-115518157-A | Application of histone deacetylase activator in preparation of low temperature resistant medicine | 广东省科学院动物研究所 | 2022-12-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12180509-B2 | Methods for reprograming non-pluripotent cells into pluripotent stem cells | AHCY, BHMT, SHMT1 | CHRM2 1118/4885ADRA2A 1680/4885CHRM1 1264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.